Results 11 to 20 of about 7,047 (156)

Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia [PDF]

Journal of Hematology & Oncology, 2021
Background Exportin 1 (XPO1/CRM1) is a key mediator of nuclear export with relevance to multiple cancers, including chronic lymphocytic leukemia (CLL). Whole exome sequencing has identified hot-spot somatic XPO1 point mutations which we found to disrupt ...
Janek S. Walker, Zachary A. Hing, Bonnie Harrington, Jordan Baumhardt, Hatice Gulcin Ozer, Amy Lehman, Brian Giacopelli, Larry Beaver, Katie Williams, Jordan N. Skinner, Casey B. Cempre, Qingxiang Sun, Sharon Shacham, Benjamin R. Stromberg, Matthew K. Summers, Lynne V. Abruzzo, Laura Rassenti, Thomas J. Kipps, Sameer Parikh, Neil E. Kay, Kerry A. Rogers, Jennifer A. Woyach, Vincenzo Coppola, Yuh Min Chook, Christopher Oakes, John C. Byrd, Rosa Lapalombella   +26 more
doaj   +2 more sources

Inhibition of XPO1 impairs cholangiocarcinoma cell proliferation by triggering p53 intranuclear accumulation

Cancer Medicine, 2023
Background XPO1 mediates the nuclear export of several proteins, mainly tumor suppressors. KPT‐330 (Selinexor) is a selective inhibitor of XPO1 that has demonstrated good therapeutic effects in hematologic cancers.
Cheng Zhao, Ben Ma, Zi‐yi Yang, Ou Li, Shi‐lei Liu, Li‐jia Pan, Wei Gong, Ping Dong, Yi‐jun Shu   +8 more
doaj   +2 more sources

Identification of Novel Covalent XPO1 Inhibitors Based on a Hybrid Virtual Screening Strategy

Molecules, 2022
Nuclear export protein 1 (XPO1), a member of the nuclear export protein-p (Karyopherin-P) superfamily, regulates the transport of “cargo” proteins.
Zheyuan Shen, Weihao Zhuang, Kang Li, Yu Guo, Bingxue Qu, Sikang Chen, Jian Gao, Jing Liu, Lei Xu, Xiaowu Dong, Jinxin Che, Qimeng Li   +11 more
doaj   +2 more sources

Exportin 1 (XPO1) Expression and Effectiveness of XPO1 Inhibitor Against Canine Lymphoma Cell Lines

Veterinary Sciences
Lymphoma is the most common neoplasm of lymphoid tissues in dogs. Exportin 1 (XPO1) is an important major nuclear receptor for exporting proteins and RNA species.
Hardany Primarizky, Satoshi Kambayashi, Kenji Baba, Kenji Tani, Masaru Okuda   +4 more
doaj   +2 more sources

XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy [PDF]

Journal of Hematology & Oncology, 2017
Many recent publications highlight the large role of the pivotal eukaryotic nuclear export protein exportin-1 (XPO1) in the oncogenesis of several malignancies, and there is emerging evidence that XPO1 inhibition is a key target against cancer.
Vincent Camus, Hadjer Miloudi, Antoine Taly, Brigitte Sola, Fabrice Jardin   +4 more
doaj   +2 more sources

Targeting deubiquitinase USP7-mediated stabilization of XPO1 contributes to the anti-myeloma effects of selinexor

Journal of Translational Medicine
Background Targeting exportin1 (XPO1) with Selinexor (SEL) is a promising therapeutic strategy for patients with multiple myeloma (MM). However, intrinsic and acquired drug resistance constitute great challenges.
Junying Wang, Mengping Chen, Jinxing Jiang, Yike Wan, Xin Li, Minyue Zhang, Fei Xiao, Lu Zhong, Hua Zhong, Zhaoyu Qin, Jian Hou   +10 more
doaj   +2 more sources

Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems [PDF]

Scientific Reports, 2018
XPO1 has recently emerged as a viable treatment target for solid malignancies, including glioblastoma (GBM), the most common primary malignant brain tumor in adults.
Enyuan Shang, Yiru Zhang, Chang Shu, Chiaki Tsuge Ishida, Elena Bianchetti, Mike-Andrew Westhoff, Georg Karpel-Massler, Markus D. Siegelin   +7 more
doaj   +4 more sources

Exportin 1 as a Therapeutic Target to Overcome Drug Resistance in Lung Cancer [PDF]

Cells
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality, with therapeutic resistance continuing to limit long-term responses.
Maria Vittoria Di Marco, Alessandro Gasparetto, Roberto Chiarle, Claudia Voena   +3 more
doaj   +2 more sources

Modulation of anti-tumour immunity by XPO1 inhibitors [PDF]

Exploration of Targeted Anti-tumor Therapy
Exportin-1 (XPO1) is a nuclear export protein that, when overexpressed, can facilitate cancer cell proliferation and survival and is frequently overexpressed or mutated in cancer patients.
Jack G. Fisher, Laura G. Bartlett, Trinayan Kashyap, Christopher J. Walker, Salim I. Khakoo, Matthew D. Blunt   +5 more
doaj   +2 more sources

Mobilization of nuclear antiviral factors by exportin XPO1 via the actin network inhibits RNA virus replication.

PLoS Pathogens
The intricate interplay between +RNA viruses and their hosts involves the exploitation of host resources to build virus-induced membranous replication organelles (VROs) in cytosol of infected cells.
Biao Sun, Cheng-Yu Wu, Paulina Alatriste Gonzalez, Peter D Nagy   +3 more
doaj   +2 more sources